Molecular Pathology and Genomics Core

项目总结 核心C提供专业的专业和技术病理服务和基因组服务 这对该计划的成功至关重要。它通过实现支持所有人的三个首要目标来做到这一点 三个P01项目：1)提供原发人类PTCL和PDX分类所需的病理学专业知识 和小鼠PTCL模型；2)对与理解相关的生物标志物进行标准的和新的原位测试 PTCL的病理生理及其对新疗法的反应和抵抗；以及3)靶向外显子 对一大群特征良好的人类PTCL进行测序。核心以两种方式提供这些服务 性能网站，一个由Jon Aster领导的波士顿网站，将提供支持目标1和2的服务，以及 由桑迪普·戴夫领导的北卡罗来纳州第二家，该公司将提供支持目标1和目标3的服务。 AIM 1的服务依赖于核心的联合领导者乔恩·阿斯特博士，他是一名实习学者 血液病理学家，在人类和小鼠血液病理学方面有25年的经验， 补充了项目1(John Chan)的其他专业知识和获得血液恶性肿瘤的机会 包括25个机构在内的研究联盟，已经积累了1800多例T细胞淋巴瘤病例， 大多数有配对的正常组织。AIM 2服务将在波士顿提供，包括标准组织学和 免疫组织学服务和创新的多参数免疫荧光染色平台，Perkin- Elmer Vectra平台和CyCIF是一种迭代成像平台，允许评估&gt；50不同 单个FFPE幻灯片上的标记。AIM 3服务在北卡罗来纳州的表演现场由 对淋巴瘤中频繁突变的410个基因进行有针对性的外显子组测序，最初使用 从1833例PTCL和配对的正常组织中提取的DNA。

PROJECT SUMMARY Core C provides access to specialized professional and technical pathology services and genomic services that are essential to the success of the Program. It does so by carrying out 3 overarching aims that support all three P01 Projects: 1) provide pathology expertise needed for classification of primary human PTCLs and PDX and murine PTCL models; 2) perform standard and novel in situ tests for biomarkers relevant to understanding PTCL pathophysiology and its response and resistance to novel therapies; and 3) perform targeted exome sequencing of a large cohort of well-characterized human PTCLs. The Core delivers these services at two performance sites, one in Boston led by Jon Aster, which will deliver services supporting Aims 1 and 2, and the second in North Carolina led by Sandeep Dave, which will deliver services supporting Aims 1 and 3. Delivery of Aim 1 services relies on the Core's co-leader, Dr. Jon Aster, who is a practicing academic hematopathologist with >25 years of experience with human and murine hematopathology, and is supplemented by additional expertise in Project 1 (John Chan) and access to the Hematologic Malignancies Research Consortium, which includes >25 institutions and has accrued over 1800 cases of T cell lymphomas, a majority with paired normal tissue. Aim 2 services will be provided in Boston include standard histology and immunohistology services and innovative, multiparametric immunofluorescence staining platforms, the Perkin- Elmer Vectra platform and CyCIF is an iterative imaging platform that allows for evaluation of >50 different markers on single FFPE slides. Aim 3 services are delivered at the North Carolina performance site by performing targeted exome sequencing on 410 genes that are frequently mutated in lymphoma, initially using DNA prepared from a cohort of 1833 PTCLs and paired normal tissue controls.